|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang J, Xu R, Wang C, Qiu J, Ren B and You
L: Early screening and diagnosis strategies of pancreatic cancer: A
comprehensive review. Cancer Commun (Lond). 41:1257–1274. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Park W, Chawla A and O'Reilly EM:
Pancreatic cancer: A review. JAMA. 326:851–862. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Habib JR, Pasha S, Khan S, Kinny-Köster B,
Shoucair S, Thompson ED, Yu J, Lafaro K, Burkhart RA, Burns WR, et
al: Ovarian metastasis from pancreatic ductal adenocarcinoma. World
J Surg. 45:3157–3164. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jin T, Dai C and Xu F: Surgical and local
treatment of hepatic metastasis in pancreatic ductal
adenocarcinoma: Recent advances and future prospects. Ther Adv Med
Oncol. Jun 23–2020.(Epub ahead of print). View Article : Google Scholar
|
|
7
|
Shah A, Korrapati P, Siegel J and Kasmin
F: Rare metastasis of primary pancreatic adenocarcinoma to the
bladder. ACG Case Rep J. 5:e272018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
de Waal YR, Thomas CM, Oei AL, Sweep FC
and Massuger LF: Secondary ovarian malignancies: Frequency, origin,
and characteristics. Int J Gynecol Cancer. 19:1160–1165. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chun YS, Pawlik TM and Vauthey JN: 8th
edition of the AJCC cancer staging manual: Pancreas and
hepatobiliary cancers. Ann Surg Oncol. 25:845–847. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schwartz LH, Seymour L, Litière S, Ford R,
Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, et
al: RECIST 1.1-standardisation and disease-specific adaptations:
Perspectives from the RECIST working group. Eur J Cancer.
62:138–145. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
U.S. Department of Health and Human
Services; National Institutes of Health and the National Cancer
Institute, : Commn Terminology Criteria for Adverse Events (CTCAE).
V4.03. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5×7.pdfMay
17–2010
|
|
12
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chu LC, Goggins MG and Fishman EK:
Diagnosis and detection of pancreatic cancer. Cancer J. 23:333–342.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gourgou-Bourgade S, Bascoul-Mollevi C,
Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A,
Raoul JL, Boige V, et al: Impact of FOLFIRINOX compared with
gemcitabine on quality of life in patients with metastatic
pancreatic cancer: Results from the PRODIGE 4/ACCORD 11 randomized
trial. J Clin Oncol. 31:23–29. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Christenson ES, Jaffee E and Azad NS:
Current and emerging therapies for patients with advanced
pancreatic ductal adenocarcinoma: A bright future. Lancet Oncol.
21:e135–e145. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Patnaik A, Kang SP, Rasco D, Papadopoulos
KP, Elassaiss-Schaap J, Beeram M, Drengler R, Chen C, Smith L,
Espino G, et al: Phase I study of pembrolizumab (MK-3475; Anti-PD-1
monoclonal antibody) in patients with advanced solid tumors. Clin
Cancer Res. 21:4286–4293. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Marabelle A, Le DT, Ascierto PA, Di
Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M,
Penel N, Hansen AR, et al: Efficacy of pembrolizumab in patients
with noncolorectal high microsatellite instability/mismatch
repair-deficient cancer: Results from the phase II KEYNOTE-158
study. J Clin Oncol. 38:31–10. 2020. View Article : Google Scholar
|
|
20
|
Marabelle A, Fakih M, Lopez J, Shah M,
Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin
JA, Miller WH Jr, et al: Association of tumour mutational burden
with outcomes in patients with advanced solid tumours treated with
pembrolizumab: Prospective biomarker analysis of the multicohort,
open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21:1353–1365.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tempero MA: NCCN guidelines updates:
Pancreatic cancer. J Natl Compr Canc Netw. 17:603–605.
2019.PubMed/NCBI
|
|
22
|
Markham A and Keam SJ: Camrelizumab: First
global approval. Drugs. 79:1355–1361. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Padrón LJ, Maurer DM, O'Hara MH, O'Reilly
EM, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, et
al: Sotigalimab and/or nivolumab with chemotherapy in first-line
metastatic pancreatic cancer: Clinical and immunologic analyses
from the randomized phase 2 PRINCE trial. Nat Med. 28:1167–1177.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tempero M, Oh DY, Tabernero J, Reni M, Van
Cutsem E, Hendifar A, Waldschmidt DT, Starling N, Bachet JB, Chang
HM, et al: Ibrutinib in combination with nab-paclitaxel and
gemcitabine for first-line treatment of patients with metastatic
pancreatic adenocarcinoma: Phase III RESOLVE study. Ann Oncol.
32:600–608. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kubeček O, Laco J, Špaček J, Petera J,
Kopecký J, Kubečková A and Filip S: The pathogenesis, diagnosis,
and management of metastatic tumors to the ovary: A comprehensive
review. Clin Exp Metastasis. 34:295–307. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Al-Agha OM and Nicastri AD: An in-depth
look at krukenberg tumor: An overview. Arch Pathol Lab Med.
130:1725–1730. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yamanishi Y, Koshiyama M, Ohnaka M, Ueda
M, Ukita S, Hishikawa K, Nagura M, Kim T, Hirose M, Ozasa H and
Shirase T: Pathways of metastases from primary organs to the
ovaries. Obstet Gynecol Int. 2011:6128172011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Prat J: Ovarian carcinomas, including
secondary tumors: Diagnostically challenging areas. Mod Pathol. 18
(Suppl 2):S99–S111. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sodek KL, Murphy KJ, Brown TJ and
Ringuette MJ: Cell-cell and cell-matrix dynamics in intraperitoneal
cancer metastasis. Cancer Metastasis Rev. 31:397–414. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Taylor EC, Irshaid L and Mathur M:
Multimodality imaging approach to ovarian neoplasms with pathologic
correlation. Radiographics. 41:289–315. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ansari D, Rosendahl A, Elebro J and
Andersson R: Systematic review of immunohistochemical biomarkers to
identify prognostic subgroups of patients with pancreatic cancer.
Br J Surg. 98:1041–1055. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nath S, Daneshvar K, Roy LD, Grover P,
Kidiyoor A, Mosley L, Sahraei M and Mukherjee P: MUC1 induces drug
resistance in pancreatic cancer cells via upregulation of multidrug
resistance genes. Oncogenesis. 2:e512013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Park JH and Kim JH: Pathologic
differential diagnosis of metastatic carcinoma in the liver. Clin
Mol Hepatol. 25:12–20. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dabir PD, Svanholm H and Christiansen JJ:
SATB2 is a supplementary immunohistochemical marker to CDX2 in the
diagnosis of colorectal carcinoma metastasis in an unknown primary.
APMIS. 126:494–500. 2018. View Article : Google Scholar : PubMed/NCBI
|
